185 related articles for article (PubMed ID: 21135181)
1. Tigecycline exhibits inhibitory activity against Clostridium difficile in the colon of mice and does not promote growth or toxin production.
Jump RL; Li Y; Pultz MJ; Kypriotakis G; Donskey CJ
Antimicrob Agents Chemother; 2011 Feb; 55(2):546-9. PubMed ID: 21135181
[TBL] [Abstract][Full Text] [Related]
2. Effects of tigecycline and vancomycin administration on established Clostridium difficile infection.
Theriot CM; Schumacher CA; Bassis CM; Seekatz AM; Young VB
Antimicrob Agents Chemother; 2015 Mar; 59(3):1596-604. PubMed ID: 25547352
[TBL] [Abstract][Full Text] [Related]
3. Tigecycline suppresses toxin A and B production and sporulation in Clostridium difficile.
Aldape MJ; Heeney DD; Bryant AE; Stevens DL
J Antimicrob Chemother; 2015 Jan; 70(1):153-9. PubMed ID: 25151204
[TBL] [Abstract][Full Text] [Related]
4. Beneficial effect of oral tigecycline treatment on Clostridium difficile infection in gnotobiotic piglets.
Kim HB; Zhang Q; Sun X; Beamer G; Wang Y; Tzipori S
Antimicrob Agents Chemother; 2014 Dec; 58(12):7560-4. PubMed ID: 25267665
[TBL] [Abstract][Full Text] [Related]
5. Tigecycline does not induce proliferation or cytotoxin production by epidemic Clostridium difficile strains in a human gut model.
Baines SD; Saxton K; Freeman J; Wilcox MH
J Antimicrob Chemother; 2006 Nov; 58(5):1062-5. PubMed ID: 17030519
[TBL] [Abstract][Full Text] [Related]
6. Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice.
Adams DA; Riggs MM; Donskey CJ
Antimicrob Agents Chemother; 2007 Aug; 51(8):2674-8. PubMed ID: 17562807
[TBL] [Abstract][Full Text] [Related]
7. Effect of antibiotic treatment on growth of and toxin production by Clostridium difficile in the cecal contents of mice.
Pultz NJ; Donskey CJ
Antimicrob Agents Chemother; 2005 Aug; 49(8):3529-32. PubMed ID: 16048976
[TBL] [Abstract][Full Text] [Related]
8. In vitro and in vivo antibacterial evaluation of cadazolid, a new antibiotic for treatment of Clostridium difficile infections.
Locher HH; Seiler P; Chen X; Schroeder S; Pfaff P; Enderlin M; Klenk A; Fournier E; Hubschwerlen C; Ritz D; Kelly CP; Keck W
Antimicrob Agents Chemother; 2014; 58(2):892-900. PubMed ID: 24277020
[TBL] [Abstract][Full Text] [Related]
9. Intravenous tigecycline in the treatment of severe recurrent Clostridium difficile colitis.
Cheong EY; Gottlieb T
Med J Aust; 2011 Apr; 194(7):374-5. PubMed ID: 21470094
[No Abstract] [Full Text] [Related]
10. Effect of ceftobiprole treatment on growth of and toxin production by Clostridium difficile in cecal contents of mice.
Nerandzic MM; Donskey CJ
Antimicrob Agents Chemother; 2011 May; 55(5):2174-7. PubMed ID: 21343463
[TBL] [Abstract][Full Text] [Related]
11.
Kester JC; Brubaker DK; Velazquez J; Wright C; Lauffenburger DA; Griffith LG
Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31988098
[TBL] [Abstract][Full Text] [Related]
12. Gastrointestinal colonization with a cephalosporinase-producing bacteroides species preserves colonization resistance against vancomycin-resistant enterococcus and Clostridium difficile in cephalosporin-treated mice.
Stiefel U; Nerandzic MM; Pultz MJ; Donskey CJ
Antimicrob Agents Chemother; 2014 Aug; 58(8):4535-42. PubMed ID: 24867962
[TBL] [Abstract][Full Text] [Related]
13. Activity of omadacycline in vitro against Clostridioides difficile and preliminary efficacy assessment in a hamster model of C. difficile-associated diarrhoea.
Leahy RG; Serio AW; Wright K; Traczewski MM; Tanaka SK
J Glob Antimicrob Resist; 2022 Sep; 30():96-99. PubMed ID: 35500838
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo activities of nitazoxanide against Clostridium difficile.
McVay CS; Rolfe RD
Antimicrob Agents Chemother; 2000 Sep; 44(9):2254-8. PubMed ID: 10952564
[TBL] [Abstract][Full Text] [Related]
15. Prevention of Clostridium difficile spore formation by sub-inhibitory concentrations of tigecycline and piperacillin/tazobactam.
Garneau JR; Valiquette L; Fortier LC
BMC Infect Dis; 2014 Jan; 14():29. PubMed ID: 24422950
[TBL] [Abstract][Full Text] [Related]
16. Alteration of the murine gastrointestinal microbiota by tigecycline leads to increased susceptibility to Clostridium difficile infection.
Bassis CM; Theriot CM; Young VB
Antimicrob Agents Chemother; 2014 May; 58(5):2767-74. PubMed ID: 24590475
[TBL] [Abstract][Full Text] [Related]
17. An in vitro culture model to study the dynamics of colonic microbiota in Syrian golden hamsters and their susceptibility to infection with Clostridium difficile.
Miezeiewski M; Schnaufer T; Muravsky M; Wang S; Caro-Aguilar I; Secore S; Thiriot DS; Hsu C; Rogers I; DeSantis T; Kuczynski J; Probst AJ; Chehoud C; Steger R; Warrington J; Bodmer JL; Heinrichs JH
ISME J; 2015 Feb; 9(2):321-32. PubMed ID: 25036923
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of OPT-80 tested against clinical isolates of toxin-producing Clostridium difficile.
Karlowsky JA; Laing NM; Zhanel GG
Antimicrob Agents Chemother; 2008 Nov; 52(11):4163-5. PubMed ID: 18725442
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the efficacy of ramoplanin and vancomycin in both in vitro and in vivo models of clindamycin-induced Clostridium difficile infection.
Freeman J; Baines SD; Jabes D; Wilcox MH
J Antimicrob Chemother; 2005 Oct; 56(4):717-25. PubMed ID: 16143709
[TBL] [Abstract][Full Text] [Related]
20. Nondigestible oligosaccharides enhance bacterial colonization resistance against Clostridium difficile in vitro.
Hopkins MJ; Macfarlane GT
Appl Environ Microbiol; 2003 Apr; 69(4):1920-7. PubMed ID: 12676665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
